ORCID Profile
0000-0001-6856-6332
Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the Feedback Form.
Publisher: American Chemical Society (ACS)
Date: 13-12-2021
DOI: 10.1021/ACS.JMEDCHEM.1C01423
Abstract: The urokinase plasminogen activator (uPA) plays a critical role in tumor cell invasion and migration and is a promising antimetastasis target. 6-Substituted analogues of 5-
Publisher: Elsevier BV
Date: 09-2016
Publisher: Elsevier BV
Date: 11-2014
DOI: 10.1016/J.EJMECH.2014.10.015
Abstract: A series of new oxadiazoline-substituted naphthalenyl acetates 3a-e and oxadiazoline-substituted 4-methoxynaphthalenyl acetates 7b-e were synthesized and tested by the National Cancer Institute (NCI) for their in vitro anticancer activity. The two derivatives bearing acetoxy groups at the 1 and 3 positions of the phenyl ring 3c and 7c were the most active showing significant anticancer activity against all tested cancer cell lines, with GI50 values ranging from 0.175 to 3.91 μM, and 0.306-11.7 μM, respectively. The selectivity of compound 3c was greater for non-solid tumor cell lines. Computational prediction of molecular and pharmacokinetic properties revealed that both compounds are safe and compound 7c had a good drug-likeness score.
Publisher: Wiley
Date: 12-07-2016
Abstract: A series of new sulfanyltriazolylnaphthalenols (10a-f and 13a-f) and sulfanyltriazolylnaphthalene-1,4-diones (14a-f) were synthesized and evaluated against a panel of cancer cell lines. Among the tested compounds, 10b and 10d showed the best anti-proliferative activity with GI50 values ranging from 2.72 to 10 and 3.13 to 13.1 µM, respectively, in several of the tumor cell lines tested. Compound 10d is highly selective toward leukemia cell lines and can be regarded as a good model for the development of new anti-leukemic agents.
Publisher: Elsevier BV
Date: 08-2019
Publisher: Springer Science and Business Media LLC
Date: 09-12-2012
Publisher: Springer Science and Business Media LLC
Date: 06-01-2022
Publisher: Springer Science and Business Media LLC
Date: 27-11-2017
Publisher: Springer Science and Business Media LLC
Date: 13-05-2012
Location: Australia
No related grants have been discovered for Nehad Elsalamouny.